

ESC Council of Cardio-Oncology Certification in cardio-oncology

Suggested reading list

The Cardio-Oncology exam is designed to test a wide range of cardio-oncology knowledge aligned with the [European Society of Cardiology Core Curriculum for cardio-oncology](#).

There is no single source from which all questions are developed, and candidates are encouraged to read widely, including but not limited to:

- **2022 ESC Guidelines on cardio-oncology.** *Eur Heart J* 2022; 43:4229–4361.
- **European Society of Cardiology Core Curriculum for cardio-oncology.** *Eur J Heart Fail.* 2024 Apr;26(4):754–771. doi: 10.1002/ejhf.3102. Epub 2023 Dec 20.
- **Hallmarks of Cancer: New Dimensions.** *Cancer Discov* 2022 Jan;12(1):31–46.
- **Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies:** a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. *Eur J Heart Fail* 2020; 22:1945–1960.
- **Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies:** a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). *Eur J Heart Fail* 2020; 22:1504–1524.
- **Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies:** a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. *Eur J Heart Fail* 2020; 22:1966–1983.
- **Defining cardiovascular toxicities of cancer therapies:** an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J* 2022; 43:280–299.
- **2016 ESC Position Paper on cancer treatments and cardiovascular toxicity** developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016; 37:2768–2801.
- **Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group.** *Eur Heart J.* 2025 Feb 28;ehaf100. doi: 10.1093/eurheartj/ehaf100.
- **ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe.** *Ann Oncol.* 2022 Nov;33(11):1119–1133.

- **Evaluation and management of cancer patients presenting with acute cardiovascular disease:** a consensus document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio Oncology—Part 1: acute coronary syndromes and acute pericardial diseases. *EHJ Acute CV Care* 2021; 10:947–959.
- **Evaluation and management of cancer patients presenting with acute cardiovascular disease:** a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-oncology - Part 2: Acute Heart Failure, Acute myocardial diseases, Acute Venous Thromboembolic Diseases and Acute Arrhythmias. *Eur Heart J Acute Cardiovasc Care*. 2022 Nov 30;11(11):865-874.
- **Cardio-oncology Services: rationale, organization, and implementation:** A report from the ESC Cardio-oncology council. *Eur Heart J* 2019; 40:1756–1763.
- **European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.** *European Heart Journal - Quality of Care and Clinical Outcomes*; 9 (1): 1-7.
- **Common mechanistic pathways in cancer and heart failure.** A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). *Eur J Heart Fail*. 2020 Dec;22(12):2272-2289.
- **Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology** *Eur J Heart Fail*. 2024 Oct;26(10):2055-2076. doi: 10.1002/ejhf.3340. Epub 2024 Aug 1.
- **The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology** *Eur J Heart Fail*. 2024 Oct;26(10):2077-2093. doi: 10.1002/ejhf.3412. Epub 2024 Aug 28.
- **Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives.** A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart *Eur J Heart Fail*. 2025 Mar 11. doi: 10.1002/ejhf.3636. Online ahead of print.
- **Breast cancer and cardiovascular health.** *Eur Heart J*. 2024 Nov 7;45(41):4366-4382. doi: 10.1093/eurheartj/ehae637.
- **Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.** *Eur Heart J*. 2024 Nov 7;45(41):4414-4424. doi: 10.1093/eurheartj/ehae574.
- **Use of new and emerging cancer drugs: what the cardiologist needs to know.** *Eur Heart J*. 2024 Jun 7;45(22):1971-1987. doi: 10.1093/eurheartj/ehae161.
- **Ischaemic heart disease in patients with cancer.** *Eur Heart J*. 2024 Apr 7;45(14):1209-1223. doi: 10.1093/eurheartj/ehae047.
- **Non-bacterial thrombotic endocarditis: clinical and pathophysiological reappraisal.** *Eur Heart J*. 2025 Jan 16;46(3):236-249. doi: 10.1093/eurheartj/ehae788.
- **A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer** *Eur Heart J* . 2022 Jul 14;43(27):2562-2569. doi: 10.1093/eurheartj/ehab843.

- **Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapy.** JACC Cardio Oncol. 2025 Feb 27:S2666-0873(25)00071-7. doi: 10.1016/j.jacc.2025.01.012. Online ahead of print.
- **Multimodality Imaging in the Diagnostic Work-Up of Patients With Cardiac Masses: JACC: CardioOncology State-of-the-Art Review** JACC CardioOncol. 2024 Oct 29;6(6):847-862. doi: 10.1016/j.jacc.2024.09.006. eCollection 2024 Dec.
- **Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association.** Circulation. 2022 Apr 12;145(15):e811-e838. doi: 10.1161/CIR.0000000000001056. Epub 2022 Mar 7.
- **Cardio-Oncology and Heart Failure: A Scientific Statement From the Heart Failure Society of America.** J Card Fail. 2025 Feb;31(2):415-455. doi: 10.1016/j.cardfail.2024.08.045. Epub 2024 Oct 15.